PRE-PROGRAM*
DAY 1 : February 24
14:55
Predict to prevent brain diseases’ progression : application to clinical trial design and patient identification
Stanley Durrleman, INRIA Researcher at ICM, INRIA
14:30
Synthetic data: utility, privacy and evaluation
Stéphanie Allassonnière, Professor, Université Paris Cité médecine
14:05
Digital twin applications for increasing trial efficiency
Devanarayan Viswanath, Head Clinical Data Science, Eisai, Inc
12:30
Break
12:05
Impact on regulatory decision making and the lifecycle of uncertainty
Cécile Ollivier, Senior Vice President Global Affairs, Critical Path Institute)
11:40
From trial data to HTA dossier: what LLM automation changes in practice
Bill Malcolm, Executive Director - EAI GHEOR, Bristol Myers Squibb
11:15
Current practice: the US perspective and the global trends
Tina Morrison, Global Harmonization Task Force Leader, Avicenna Alliance
10:45
Break
10:20
Case Study in MHRA sandbox: Using Synthetic Data to Enable Robust Subgroup Analysis in a Pivotal RRMM Trial
Federico Mattiello, Biostatistician, Roche
09:55
Virtual patients in drug development and regulatory decision making
Piet van der Graaf, Senior Vice President QSP & Professor of Systems Pharmacology and Pediatrics, Certara
09:30
Model-informed development: what qualifies as fit-for-purpose
Flora Musuamba, Professor, Université de Namur
09:00
Regulatory opening: where the agency stands
MORNING
AI-enabled evidence in regulatory and HTA practice today
AFTERNOON
Methods in the making
15:20
Break
15:45
Tabular foundation models: one pass, no training. What changes for clinical evidence?
Marine Le Morvan, Research Scientist, INRIA
16:10
Three submitted communications
16:40
Reusable models versus ad-hoc analyses
Billy Amzal, Program intelligence, modeling and AI for Global Health, Gates Foundation
DAY 2 : February 25
11:00
How biostatistics evolves through systematic AI use
Marc Buyse, Founder of IDDI
10:35
Three submitted communications
10:05
Break
09:40
RWE agencies will trust
Olaf Klungel, Professor Pharmacoepidemiologic Methods, Utrecht University
09:15
What regulators could do with trial data, and why they have not
08:50
DARWIN EU: building the foundations for AI-enabled evidence generation
11:30
Data access as the binding constraint
Wim Goettsch, Coördinator, SUSTAIN-HTA
12:00
Break
13:30
When AI writes the report: the inspection burden
13:55
AI use in biostatistics - safely collaborating with agents in a high-stakes, regulated setting
Peter Krusche, Global Head, AI & Data Engineering, Novartis
14:20
Mechanistic Modeling hybridized with Agentic AI
Frédéric Cogny, Co-Chief Executive Officer Nova In Silico
14:45
Break
15:00
The unmet needs: what no method answers yet
MORNING
Data & biostatistics as the foundation
AFTERNOON
The generative turn and the regulatory response
16:15
Closing remarks and outlook to 2028
* currently under development and subject to change.
.png)